supplement to: Baricitinib versus placebo or adalimumab in rheumatoid arthritis.

By P. Taylor, E. Keystone, D. M. van der Heijde, Michael E. Weinblatt, Liliana del Carmen Morales, J.Reyes Gonzaga, S. Yakushin, T. Ishii, K. Emoto, S. Beattie and 7 more. 2017

780 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/0aa600c6498e5298894b1ff542fd54c898699582

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Martina Anzaghe
2. Yen-Ju Lin
3. S. Schülke

Citations in the corpus

• Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis (2020, background): “In a 52-week, phase 3, double-blind, placebo- and active-controlled trial including 1307 patients with active RA that were receiving background therapy with methotrexate, 70% of patients treated with 4 mg baricitinib daily (a dose twice as high as the 2 mg dose approved by the FDA) reached ACR20 at ”
• Diagnosis and Management of Rheumatoid Arthritis: A Review (2018, unknown): “Combined with methotrexate, baricitinib had better efficacy than adalimumab.(81)”